895240-77-4

Usage

Uses

Used in Cardiovascular Applications:
4-Ethyl-3-(3-methoxypropoxyl)benzoic acid is used as an antiplatelet agent for preventing the formation of blood clots in patients who have undergone cardiovascular procedures such as angioplasty. It achieves this by blocking the glycoprotein IIb/IIIa receptor on platelet surfaces, thereby reducing the risk of complications like heart attacks and strokes.
Used in Hospital Settings:
4-Ethyl-3-(3-methoxypropoxyl)benzoic acid is used as an intravenous medication in hospital settings under the supervision of healthcare professionals. This ensures that patients receive the appropriate dosage and monitoring for potential side effects such as bleeding, bruising, and dizziness, which are crucial for maintaining patient safety and therapeutic outcomes.

Upstream product

• 895240-80-9 4-ethynyl-3-(3-methoxy-propoxy)-benzoic acid 
• 14348-38-0 4-bromo-3-hydroxybenzoic acid 
• 106291-80-9 methyl 4-bromo-3-hydroxybenzoate 
• 895240-79-6 3-(3-methoxy-propoxy)-4-trimethylsilanylethynyl-benzoic acid methyl ester 
• 895240-78-5 4-bromo-3-(3-methoxy-propoxy)-benzoic acid methyl ester 

Relevant academic research and scientific papers

The P1 N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin

Novel nonpeptide small molecule renin inhibitors bearing an N-isopropyl P1 motif were designed based on initial lead structures 1 and aliskiren (2). (P3-P1)-Benzamide derivatives such as 9a and 34, as well as the corresponding P1 basic tertiary amine derivatives 10 and 35 were found to display low nanomolar inhibition against human renin in vitro.

3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION

The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis. The substituted pyrrolidine compounds are of the formula (I), wherein R1, R2, R3, R4, R5 and T are defined as in the specification.